These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 14714403)
21. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Patel GB; Zhou H; Ponce A; Chen W Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279 [TBL] [Abstract][Full Text] [Related]
22. [Factors, mediating the immunomodulating effect of met-enkephalin: effect of mitogen dose, stage of cellular activation, and time of opioid introduction]. Dubinin KV; Zakharova LA Biull Eksp Biol Med; 1995 Apr; 119(4):398-401. PubMed ID: 7620139 [No Abstract] [Full Text] [Related]
23. A need for effective adjuvants. Bunce CJ; Morse MA Curr Opin Mol Ther; 2003 Feb; 5(1):8-9. PubMed ID: 12669464 [No Abstract] [Full Text] [Related]
24. Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis. Clark S; Cross ML; Smith A; Court P; Vipond J; Nadian A; Hewinson RG; Batchelor HK; Perrie Y; Williams A; Aldwell FE; Chambers MA Vaccine; 2008 Oct; 26(46):5791-7. PubMed ID: 18789366 [TBL] [Abstract][Full Text] [Related]
25. Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice. Patel GB; Ponce A; Zhou H; Chen W Int J Toxicol; 2008; 27(4):329-39. PubMed ID: 18821397 [TBL] [Abstract][Full Text] [Related]
26. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. Chong CS; Cao M; Wong WW; Fischer KP; Addison WR; Kwon GS; Tyrrell DL; Samuel J J Control Release; 2005 Jan; 102(1):85-99. PubMed ID: 15653136 [TBL] [Abstract][Full Text] [Related]
27. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. Kojima N; Biao L; Nakayama T; Ishii M; Ikehara Y; Tsujimura K J Control Release; 2008 Jul; 129(1):26-32. PubMed ID: 18485512 [TBL] [Abstract][Full Text] [Related]
28. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264 [TBL] [Abstract][Full Text] [Related]
30. Retro-engineering of liposomal vaccine adjuvants: role of a microarray-based screen. Pattani A; Malcolm RK; Curran RM Vaccine; 2010 Feb; 28(6):1438-9. PubMed ID: 20003925 [No Abstract] [Full Text] [Related]
31. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624 [TBL] [Abstract][Full Text] [Related]
32. Chitosan-based systems for the delivery of vaccine antigens. Arca HC; Günbeyaz M; Senel S Expert Rev Vaccines; 2009 Jul; 8(7):937-53. PubMed ID: 19538118 [TBL] [Abstract][Full Text] [Related]
35. Immunomodulatory activities of fractions from hot aqueous extract of wood from Clausena excavata. Manosroi A; Saraphanchotiwitthaya A; Manosroi J Fitoterapia; 2004 Jun; 75(3-4):302-8. PubMed ID: 15158986 [TBL] [Abstract][Full Text] [Related]
36. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Wilson KD; de Jong SD; Tam YK Adv Drug Deliv Rev; 2009 Mar; 61(3):233-42. PubMed ID: 19232375 [TBL] [Abstract][Full Text] [Related]